[Fulminant myocarditis and COVID-19].

Rev Esp Cardiol

Department of Community Medicine, Dr. D.Y. Patil University, Pune, India.

Published: October 2020

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301081PMC
http://dx.doi.org/10.1016/j.recesp.2020.05.012DOI Listing

Publication Analysis

Top Keywords

[fulminant myocarditis
4
myocarditis covid-19]
4
[fulminant
1
covid-19]
1

Similar Publications

Fulminant myocarditis (FM) is an acute, diffuse inflammatory myocardial disease characterized by abrupt onset and extremely rapid progression. Patients typically exhibit haemodynamic abnormalities that may lead to respiratory failure, liver and renal failure, and subsequent coagulopathy. Collectively, these complications significantly increase the risk of early mortality.

View Article and Find Full Text PDF

Eosinophilic myocarditis (EM), irrespective of its unique etiology, is marked by varying extents of eosinophil infiltration, frequently accompanied by peripheral eosinophilia. In some instances, the etiology remains undetermined, thus classified as idiopathic hypereosinophilic syndrome. The clinical manifestations are highly variable, ranging from mild or asymptomatic presentations to acute fulminant myocarditis or chronic restrictive cardiomyopathy.

View Article and Find Full Text PDF

We report a rare complication of left ventricular giant thrombus in a patient with fulminant myocarditis after venoarterial extracorporeal membrane oxygenation therapy. This case report offers simple anticoagulant treatment experiences to eliminate significant LV thrombosis in patient undergoing extracorporeal membrane oxygenation, so that patients do not need surgery.

View Article and Find Full Text PDF

Background: Immune checkpoint inhibitors (ICIs) are effective antineoplastic agents but can cause adverse effects in many organ systems. Cardiovascular toxicities include arrhythmias, myocarditis, heart failure, takotsubo syndrome, pericarditis, coronary artery disease, and vasculitis.

Case Summary: A 66-year-old woman with Stage 3C2 endometrial carcinoma presented for her second cycle of pembrolizumab, carboplatin, and paclitaxel.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!